Michael B. Atkins
迈克尔·阿特金斯
MD
Deputy Director, Georgetown Lombardi Comprehensive Cancer Center; Professor of OncologyLombardi综合癌症中心副主任；肿瘤学教授
👥Biography 个人简介
Michael B. Atkins, MD is a pioneer of immunotherapy in renal cell carcinoma and melanoma, having championed high-dose IL-2 as a potentially curative option for select patients before the checkpoint inhibitor era. As Deputy Director of Georgetown Lombardi Comprehensive Cancer Center, he has led translational research bridging cytokine immunotherapy, VEGFR-targeted therapy, and contemporary IO combination strategies in RCC.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
High-Dose IL-2 Immunotherapy in RCC
Conducted and led landmark clinical trials establishing high-dose interleukin-2 as the first immunotherapy capable of inducing durable complete remissions in select patients with metastatic RCC, providing proof of concept for immune-based cure in this disease.
Pembrolizumab + Axitinib Biomarker Analysis
Led translational analyses of KEYNOTE-426, identifying angiogenic gene expression signatures and PD-L1 status as predictors of differential benefit from pembrolizumab plus axitinib versus sunitinib in first-line metastatic clear cell RCC.
Combined VEGF/PD-1 Blockade Synergy Mechanisms
Investigated the biological rationale for combining VEGFR TKIs with checkpoint inhibitors in RCC, demonstrating that VEGF pathway inhibition promotes T-cell infiltration and reduces immunosuppressive myeloid populations in the tumor microenvironment.
Risk Stratification and Prognostic Modeling in RCC
Contributed to development of the IMDC risk score and performed critical analyses distinguishing predictive from prognostic factors in the context of targeted therapy and immunotherapy in metastatic RCC.
Representative Works 代表性著作
High-dose Recombinant Interleukin 2 Therapy for Patients with Metastatic Melanoma: Analysis of 270 Patients
Cancer (1999)
Landmark analysis demonstrating durable complete remissions in approximately 6% of metastatic melanoma and RCC patients treated with high-dose IL-2, establishing proof of concept for immunological cure.
Axitinib with or without Pembrolizumab in Patients with Advanced Renal Cell Carcinoma: Biomarker Analysis of KEYNOTE-426
Nature Medicine (2022)
Translational analysis identifying angiogenic and immune gene expression signatures that predict differential benefit from pembrolizumab plus axitinib versus sunitinib in metastatic RCC.
Nivolumab plus Ipilimumab as First-line Treatment for Advanced Non-Clear-Cell Renal Cell Carcinoma
Clinical Cancer Research (2023)
Phase II trial demonstrating clinical activity of nivolumab plus ipilimumab in non-clear cell RCC histologies including papillary and chromophobe subtypes.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 迈克尔·阿特金斯 的研究动态
Follow Michael B. Atkins's research updates
留下邮箱，当我们发布与 Michael B. Atkins（Georgetown University Medical Center / MedStar Georgetown University Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment